BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalekos GN, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. Eur J Intern Med 2020;75:1-9. [PMID: 32051092 DOI: 10.1016/j.ejim.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin SZ, Chen YW, Fan JG. Non‐alcoholic fatty liver disease to metabolic dysfunction‐associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. J Dig Dis 2020;21:604-9. [DOI: 10.1111/1751-2980.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gatselis NK, Azariadis K, Lyberopoulou A, Dalekos GN. Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. J Transl Autoimmun 2021;4:100126. [PMID: 34632357 DOI: 10.1016/j.jtauto.2021.100126] [Reference Citation Analysis]
3 Dalekos GN, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. BMJ Case Rep 2020;13:e238400. [PMID: 33370951 DOI: 10.1136/bcr-2020-238400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rigopoulou EI, Gatselis N, Arvaniti P, Koukoulis GK, Dalekos GN. Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. Eur J Intern Med 2021;85:86-91. [PMID: 33451888 DOI: 10.1016/j.ejim.2020.12.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Cui Y, Wang Q, Chang R, Aboragah A, Loor JJ, Xu C. Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice. Front Pharmacol 2021;12:789430. [PMID: 34899351 DOI: 10.3389/fphar.2021.789430] [Reference Citation Analysis]
7 Yu T, Zheng E, Li Y, Li Y, Xia J, Ding Q, Hou Z, Ruan XZ, Zhao L, Chen Y. Src-mediated Tyr353 phosphorylation of IP3R1 promotes its stability and causes apoptosis in palmitic acid-treated hepatocytes. Exp Cell Res 2021;399:112438. [PMID: 33358861 DOI: 10.1016/j.yexcr.2020.112438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Araz M, Kilinc F, Kerimoglu U, Keskin M, Kucukkartallar T. Irinotecan-induced NASH and liver failure. Clin Res Hepatol Gastroenterol 2021;45:101606. [PMID: 33446474 DOI: 10.1016/j.clinre.2020.101606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gaber Y, AbdAllah M, Salama A, Sayed M, Abdel Alem S, Nafady S. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34263707 DOI: 10.1080/17474124.2021.1952867] [Reference Citation Analysis]
10 Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C. Current management of NAFLD/NASH. Liver Int 2021;41 Suppl 1:89-94. [PMID: 34155799 DOI: 10.1111/liv.14869] [Reference Citation Analysis]
11 Fu L, Wu Z, Chu Y, Chen W, Gao L, Mu S, Zhao J, Zhao E. Explore the Mechanism of Astragalus mongholicus Bunge against Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental Verification. Gastroenterology Research and Practice 2022;2022:1-17. [DOI: 10.1155/2022/4745042] [Reference Citation Analysis]
12 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice. Clin Rev Allergy Immunol 2021. [PMID: 34491531 DOI: 10.1007/s12016-021-08888-9] [Reference Citation Analysis]